MX2012012846A - Composicion oftalmica. - Google Patents

Composicion oftalmica.

Info

Publication number
MX2012012846A
MX2012012846A MX2012012846A MX2012012846A MX2012012846A MX 2012012846 A MX2012012846 A MX 2012012846A MX 2012012846 A MX2012012846 A MX 2012012846A MX 2012012846 A MX2012012846 A MX 2012012846A MX 2012012846 A MX2012012846 A MX 2012012846A
Authority
MX
Mexico
Prior art keywords
hyperbranched polyester
ophthalmic
carbonic anhydrase
increases
ophthalmic composition
Prior art date
Application number
MX2012012846A
Other languages
English (en)
Spanish (es)
Inventor
Inouejun
Tapan Shah
Original Assignee
Senju Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Usa Inc filed Critical Senju Usa Inc
Publication of MX2012012846A publication Critical patent/MX2012012846A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2012012846A 2010-05-05 2011-05-04 Composicion oftalmica. MX2012012846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/774,419 US8211450B2 (en) 2010-05-05 2010-05-05 Ophthalmic composition
PCT/US2011/035147 WO2011140194A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition

Publications (1)

Publication Number Publication Date
MX2012012846A true MX2012012846A (es) 2013-05-22

Family

ID=44902332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012846A MX2012012846A (es) 2010-05-05 2011-05-04 Composicion oftalmica.

Country Status (8)

Country Link
US (2) US8211450B2 (https=)
EP (1) EP2566487A4 (https=)
JP (1) JP2013528589A (https=)
KR (1) KR20130121685A (https=)
CN (1) CN103096901A (https=)
CA (1) CA2797123A1 (https=)
MX (1) MX2012012846A (https=)
WO (1) WO2011140194A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158722A (en) * 2010-07-29 2016-11-15 Santen Pharmaceutical Co Ltd "drug support body, and method for producing same"
WO2013114397A2 (en) * 2012-01-16 2013-08-08 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
CN103740831B (zh) * 2014-01-13 2015-01-28 宁波海尔施基因科技有限公司 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法
JP6487452B2 (ja) * 2014-01-24 2019-03-20 センティス ファーマ プライベート リミテッド ブリンゾラミドを含む医薬組成物
ES2805459T3 (es) 2014-05-16 2021-02-12 Occidental Chem Co Método para fabricar 1,1,3,3-tetracloropropeno
JP6373995B2 (ja) * 2014-07-11 2018-08-15 富士フイルム株式会社 眼科用水性組成物
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
KR101773669B1 (ko) 2015-07-30 2017-08-31 포항공과대학교 산학협력단 생체적합성 각막세포 전구체 분화방법 및 각막세포 전구체 조성물
JP6050454B1 (ja) * 2015-09-28 2016-12-21 参天製薬株式会社 水性医薬組成物
TW201733577A (zh) * 2016-03-14 2017-10-01 Santen Pharmaceutical Co Ltd 含有多佐胺、噻嗎洛爾和界面活性劑之醫藥組成物
WO2019118928A1 (en) 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids
KR20240134913A (ko) 2022-01-21 2024-09-10 센주 유에스에이, 인코포레이티드 수성 액제
CN118978426B (zh) * 2024-10-22 2025-05-16 浙江大学 一种甘油的酸化处理方法、酸化甘油及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136014A (en) * 1990-06-22 1992-08-04 E. I. Du Pont De Nemours And Company Hyperbranched polyesters
CZ285129B6 (cs) * 1991-04-17 1999-05-12 Merck & Co., Inc. Oftalmické přípravky, obsahující kombinace inhibitoru karboanhydrasy a beta-adrenergního antagonisty
US6316443B1 (en) * 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
FR2772771B1 (fr) * 1997-12-19 2000-01-28 Oreal Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US7097856B2 (en) 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
JP2004523624A (ja) 2001-02-26 2004-08-05 デューク ユニバーシティ 新規なデンドリティックポリマー、およびその生物医学的使用
AU2002304314B2 (en) 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
FR2830450B1 (fr) 2001-10-09 2004-02-06 Univ Pasteur Utilisation de dendrimeres dans une composition ophtalmique
AR038269A1 (es) 2002-01-09 2005-01-12 Novartis Ag Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
KR20050111586A (ko) * 2003-02-13 2005-11-25 내셔널 센터 포 사이언티픽 리서치 데모크리토스 드러그 및 유전자 전달 시스템으로서의 다기능의 덴드리머및 다중결합된 폴리머
JP2005008614A (ja) 2003-03-28 2005-01-13 Nano Career Kk 高分子ミセルを用いた眼科用ドラッグデリバリーシステム
US7109247B2 (en) 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7189456B2 (en) 2004-03-04 2007-03-13 Transitions Optical, Inc. Photochromic optical article
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7837986B2 (en) 2004-12-01 2010-11-23 E. I. Du Pont De Nemours And Company Protein-based polymer tissue adhesives for medical use
US20090041813A1 (en) * 2005-02-21 2009-02-12 Basf Aktiengesellschaft Active substance composition comprising at least one nitrogen atom-containing, hyperbranched polymer
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
US7666331B2 (en) 2005-08-31 2010-02-23 Transitions Optical, Inc. Photochromic article
CN104524596B (zh) 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US20090012033A1 (en) 2006-03-03 2009-01-08 Demattei Cordell R Delivery of Biologically Active Materials Using Core-Shell Tecto(Dendritic Polymers)
US20080031916A1 (en) * 2006-04-24 2008-02-07 Heather Sheardown Dendrimer cross-linked collagen
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090324742A1 (en) 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
TWI409081B (zh) * 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
US7906214B2 (en) 2007-01-26 2011-03-15 Transitions Optical, Inc. Optical elements comprising compatiblizing coatings and methods of making the same
JP5484339B2 (ja) * 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
WO2009064963A2 (en) 2007-11-14 2009-05-22 E. I. Du Pont De Nemours And Company Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US20100008993A1 (en) 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
WO2010017184A2 (en) * 2008-08-08 2010-02-11 Virginia Commonwealth University Dendrimer hydrogels

Also Published As

Publication number Publication date
EP2566487A4 (en) 2014-06-18
EP2566487A1 (en) 2013-03-13
CN103096901A (zh) 2013-05-08
CA2797123A1 (en) 2011-11-10
US8211450B2 (en) 2012-07-03
JP2013528589A (ja) 2013-07-11
KR20130121685A (ko) 2013-11-06
US20110275617A1 (en) 2011-11-10
US20130053374A1 (en) 2013-02-28
WO2011140194A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
MX2012012846A (es) Composicion oftalmica.
ES2443548T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
MX2011008731A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
EP4491225A3 (en) Treatment of erectile dysfunction and other indications
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
EP4289446A3 (en) Method and composition for treating ocular hypertension and glaucoma
MX366099B (es) Deposito de fosfolipidos.
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
WO2009135853A3 (en) Encapsulation of biologically active agents
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
JP2013525493A5 (https=)
WO2013006743A3 (en) Personal care compositions with improved solubility of a solid cosmetic active substance
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
CA2798069A1 (en) Stabilized ophthalmic galactomannan formulations
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
JP2008222638A (ja) 油成分含有眼用組成物
TW200946141A (en) Foam-shaped skin liniment
JP2015229761A (ja) 液体洗浄剤組成物
WO2008027793A3 (en) Ophthalmic pharmaceutical compositions and uses thereof
JP5984531B2 (ja) 水性眼科組成物
AU2011245442B2 (en) Pharmaceutical compositions with phosphonium antimicrobial agents
RU2012103982A (ru) Офтальмологические композиции с этиленоксид-бутиленоксидными блок-сополимерами
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
WO2018225729A1 (ja) ソフトコンタクトレンズ用眼科用組成物及びビタミンa分離抑制方法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal